ReviewFrontiers in oncology2025
Endocrine therapy for endometrial cancer: traditional approaches and novel targets.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Biomaterial-enabled multimodal therapy for endometrial cancer: Subtype-guided immuno-metabolic modulation and fertility-conscious regeneration.Materials today. Bio · 2026Article
- Endometrial Hyperplasia: Current Insights into Epidemiology, Risk Factors, and Clinical Management.Cancers · 2025Review
- Observational
- The molecular role of RE1 silencing transcription factor in uterine diseases: is there potential for targeted therapeutic development?Expert opinion on therapeutic targets · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, the global incidence of endometrial cancer is increasing. Endocrine therapy offers advantages in the management of this malignancy due to its broad applicability and favorable tolerability profile. Although conventional endocrine treatments, including progesterone, gonadotropin-releasing hormone agonists and aromatase inhibitors demonstrate efficacy in endometrial cancer, their long-term utility is limited by adverse effects such as drug resistance and disease recurrence with prolonged treatment. Novel endocrine therapeutic agents, including selective estrogen receptor modulators, selective estrogen receptor degraders, epigenetic-targeted therapies, mTOR inhibitors, cyclin-dependent kinase inhibitors, and metformin, remain in preclinical development or clinical trials. Inspiringly, the preliminary findings suggest these emerging agents may positively impact survival outcomes in endometrial cancer patients. This review examines the mechanisms, methodologies, and efficacy of both traditional and novel endocrine therapeutic approaches for endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.